Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 979-983

  Kim, Sun Hye ^a   Park, In Hae ^a,b   Lee, Hyewon ^a   Lee, Keun Seok ^b   Nam, Byung Ho ^a   Ro, Jungsil ^a,b  

^a Center for Clinical Services   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Aromatase inhibitor; Cross resistance; Exemestane; Metastatic breast cancer

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE;

ADULT; AGED; ARTICLE; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 84871675323     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.979     Document Type: Article

References (22)

1. Bertelli, G., O. Garrone, et al. (2005). Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology, 69, 471-7.
2. Bonneterre, J., B. Thurlimann, et al. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 18, 3748-57.
3. Chia, S., W. Gradishar, et al. (2008). Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol, 26, 1664-70.
4. Chin, Y. S., M. J. Beresford, et al. (2007). Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast, 16, 436-9.
5. Gennatas, C., V. Michalaki, et al. (2006). Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori, 92, 13-7.
6. Kurebayashi, J., H. Sonoo, et al. (2000). Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies. Oncology, 59, Suppl 1, 31-7.
7. Lonning, P. E. (2009). Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer, 45, 527-535.
8. Lonning, P. E., E. Bajetta, et al. (2000). Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol, 18, 2234-44.
9. Macedo, L. F., Z. Guo, et al. (2006). Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res, 66, 7775-82.
10. McShane, L. M., D. G. Altman, et al. (2005). Reporting recommendations for tumor marker prognostic studies. J Clin Oncol, 23, 9067-72.
11. Miller, W. R., T. J. Anderson, et al. (2003). An integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol, 86, 413-421.
12. Miller, W. R., J. Bartlett, et al. (2008). Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist, 13, 829-37.
13. Mouridsen, H., M. Gershanovich, et al. (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol, 21, 2101-9.
14. Muss, H. B. (1992). Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat, 21, 15-26.
15. Nabholtz, J. M., A. Buzdar, et al. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 18, 3758-67.
16. Nam, B. H., S. Y. Kim, et al. (2008). Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 10, R20.
17. Paridaens, R. J., L. Y. Dirix, et al. (2008). Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol, 26, 4883-90.
18. Santen, R. J., A. Manni, et al. (1990). Endocrine treatment of breast cancer in women. Endocr Rev, 11, 221-65.
19. Smith, I. E. and M. Dowsett (2003). Aromatase inhibitors in breast cancer. N Engl J Med, 348, 2431-42.
20. Steele, N., J. Zekri, et al. (2006). Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast, 15, 430-6.
21. Suzuki, T., Y. Miki, et al. (2007). 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer, 120, 285-91.
22. Therasse, P., S. G. Arbuck, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16.